Becton Dickinson outlines separation of biosciences and diagnostics, shares in S&P 500 medtech focus

Becton Dickinson plans to separate its biosciences and diagnostics operations into a standalone company, continuing a portfolio simplification strategy that keeps the S&P 500 medtech group on investors' radar.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 16:38.

Becton Dickinson (US0718131099) continues to work on separating its biosciences and diagnostics activities into a distinct company, a strategic move that keeps the New Jersey-based medtech group on the S&P 500 radar alongside peers such as Abbott and Medtronic. BioWorld reported on the separation plan in February 2025.

What is known about the separation

According to coverage from BioWorld, Becton Dickinson plans to split off its biosciences and diagnostic solutions unit, creating two more focused companies, with a "New BD" remaining as the core device and interventional platform. The BioWorld article from February 6, 2025 outlines the concept of a RemainCo and a spin-off entity.

The move fits a broader medtech trend where conglomerates streamline portfolios and unlock value by separating diagnostics or life-science tools from broader device businesses, a path also followed by groups like GE Healthcare and Siemens Healthineers in past years. Finanzen100 lists Becton Dickinson as part of the S&P 500 medtech cohort.

How analysts and the market view BD

Analyst sentiment on Becton Dickinson remains shaped by balance-sheet discipline and growth prospects in core medical and interventional segments, with Bank of America trimming its price target in mid-June 2026 while maintaining a cautious stance on medtech headwinds. A Finanzen.net note cited by Finanzen100 highlights the BofA target cut.

On Nasdaq, Becton Dickinson trades under the ticker BDX, with recent pricing data from TradingKey showing the shares at around 141.70 US dollars, implying a market capitalization near 40.3 billion dollars and a trailing P/E multiple in the mid-30s. TradingKey quotes BDX at 141.70 dollars with a 40.35 billion dollar market cap.

The product behind the stock

Becton Dickinson generates a large share of its revenue with medical delivery systems such as the BD Eclipse safety syringe, alongside catheters, infusion sets and diagnostic instruments used in hospitals, laboratories and clinics worldwide.

Where the stock trades today

The Becton Dickinson shares (US0718131099) trade on Nasdaq under the ticker BDX, recently quoted at about 141.70 US dollars as of 2026-06-22, 15:15, according to TradingKey data.

Key data on the Becton Dickinson shares

• Company: Becton, Dickinson and Company
• ISIN: US0718131099
• WKN: 857675
• Ticker: BDX
• Trading venue: NASDAQ
• Price (as of 2026-06-22, 15:15): 141.70 USD
• Market cap: 40.35 billion USD (as of 2026-06-22)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.